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We performed a multicenter retrospective analysis across 10 US academic medical
centers to evaluate treatment patterns and outcomes in patients age $60 years with
classic Hodgkin lymphoma (cHL) from 2010-2018. Among 244 eligible patients, median
age was 68, 63% had advanced stage (III/IV), 96% had Eastern Cooperative Oncology
Group performance status (PS) 0-2, and 12% had documented loss of $1 activity of daily
living (ADL). Medical comorbidities were assessed by the Cumulative Illness Rating
Scale–Geriatric (CIRS-G), where n 5 44 (18%) had total scores $10. Using multivariable
Cox models, only ADL loss predicted shorter progression-free (PFS; hazard ratio [HR]
2.13, P 5 .007) and overall survival (OS; HR 2.52, P 5 .02). Most patients (n 5 203, 83%)
received conventional chemotherapy regimens, including doxorubicin, bleomycin,
vinblastine, and dacarbazine (ABVD; 56%), AVD (14%), and AVD with brentuximab
vedotin (BV; 9%). Compared to alternative therapies, conventional regimens significantly
improved PFS (HR 0.46, P 5 .0007) and OS (HR 0.31, P 5 .0003). Survival was similar
following conventional chemotherapy in those ages 60-69 vs $70: PFS HR 0.88, P 5 .63;
OS HR 0.73, P 5 .55. Early treatment discontinuation due to toxicity was more common
with CIRS-G $10 (28% vs 12%, P 5 .016) or documented geriatric syndrome (28% vs 13%,
P 5 .02). A competing risk analysis demonstrated improved disease-related survival with
conventional therapy (HR 0.29, P 5 .02) and higher mortality from causes other than
disease or treatment with high CIRS-G or geriatric syndromes. This study suggests
conventional chemotherapy regimens remain a standard of care in fit older patients with
cHL, and highlights the importance of geriatric assessments in defining fitness for cHL
therapy going forward.
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Introduction
Patients age .60 years represent 20% to 30% of new classical
Hodgkin lymphoma (cHL) diagnoses annually but remain vastly
underrepresented in clinical trials, comprising only 5% to 13% of
participants in modern phase 3 studies.1-5 These individuals more
commonly present with advanced-stage disease, mixed cellularity
subtype, and varying burdens of age-related medical comorbidities,
all of which may affect fitness for and outcomes with conventional
cHL regimens such as doxorubicin, bleomycin, vinblastine, and
dacarbazine (ABVD) and Stanford V.2,6,7 Older patients have histori-
cally experienced inferior efficacy and greater toxicity with these reg-
imens compared with younger individuals with cHL.8 However, it
remains unclear how these experiences compare in the context of
novel combinations without a conventional chemotherapy back-
bone,9-11 particularly in those who otherwise seem fit enough to
receive intensive therapy.
Geriatric fitness measures have been increasingly studied across
oncologic settings and may allow for more objective insight into a
patient’s candidacy for a proposed treatment intensity.12 Although
geriatric assessment (GA) has been studied extensively in the man-
agement of older patients with solid tumors, data are more limited in
hematologic malignancies, and it is unknown how widely GA is
used in the United States to inform decisions on lymphoma-directed
therapy in routine practice.13 Medical comorbidity burden, a key
component of geriatric fitness testing, has been shown in multiple
cHL studies to affect the tolerability and efficacy of a given regi-
men.14,15 Functional impairment of basic and/or instrumental activi-
ties of daily living (ADLs) has likewise been shown to have a
significant impact on treatment tolerability and disease-related
outcomes, in geriatric oncology more broadly and cHL in
particular.15-17
Given the wide range of current treatment options available to older
cHL patients as well as the impact that a more nuanced assess-
ment of geriatric fitness may have on treatment consideration and
outcomes, we performed a large retrospective analysis to assess
real-world outcomes in this population.
Methods
Eligibility
After institutional review board approval was obtained at each site,
we collected detailed clinical and pathologic data from patients with
cHL across 10 US academic medical centers. Eligible patients
were age $60 years at the time of cHL diagnosis and started on
lymphoma-directed therapy between January 2010 and December
2018. A total of 264 patients were identified, of whom 244 met full
eligibility for inclusion. Those with a preceding hematologic malig-
nancy (n 5 4) or inadequate clinicopathologic or outcome data (n
5 16) were excluded; no cases of nodular lymphocyte-predominant
HL were submitted. The study was conducted in accordance with
the Declaration of Helsinki.
Variables and end points
Medical comorbidities were quantified by the Cumulative Illness Rat-
ing Scale–Geriatric (CIRS-G), a validated assessment tool specifi-
cally designed to capture comorbidities in older individuals18; cHL
was not included in CIRS-G scoring. Data regarding ADLs and
presence of a geriatric syndrome (dementia, delirium, depression,
osteoporosis, incontinence, falls, failure to thrive, and/or neglect/
abuse) were abstracted from patient medical records. Treatment
response and progression were determined by local investigators
and clinical documentation. Survival estimates were calculated for
progression-free (PFS; time from cHL diagnosis to disease progres-
sion, death, or last follow-up) and overall survival (OS; time from
diagnosis to death or last follow-up).
In assessing frontline therapy, we compared recipients of conven-
tional cHL regimens (defined here as ABVD; doxorubicin, vinblas-
tine, and dacarbazine [AVD] with or without brentuximab vedotin
[BV]; or Stanford V) with those who received alternative regimens
(ie, all other therapies). Although anthracyclines are considered nec-
essary for curative-intent therapy in cHL,19 we did not consider
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)
a conventional cHL regimen for these analyses, given the substantial
differences in dose density, which has been shown in cHL to affect
response rates and survival, between CHOP and A(B)VD.20 On the
basis of this decision, a separate 3-arm comparison was also per-
formed to assess PFS and OS after CHOP relative to conventional
and non-CHOP alternative therapies. Growth factor use and chemo-
therapy dose adjustments were not collected.
Statistical methods
Data were deidentified before submission for analysis, including the
censoring of age as $90 years for relevant cases. Categorical data
were analyzed using the x2 test, the Fisher exact test, and logistic
regression modeling. Continuous variable data were compared
using the 2-sample Student t test. Kaplan-Meier estimates and the
log-rank test were used for time-to-event analyses. Findings signifi-
cant on univariate analysis were subsequently assessed in multivari-
able logistic regression models. Associations of baseline patient
characteristics with survival were further evaluated using a multivari-
able Cox proportional hazards model, using backward elimination to
help mitigate potential collinearity between factors and using a vari-
able retention threshold of 0.05. Analyses were performed in SAS
(version 9.4; SAS institute, Cary NC), and figures were created
using GraphPad Prism (version 8; GraphPad Software, Inc., San
Diego, CA).
Multivariate competing-risk regression based on the Fine-Gray
method21 was conducted using the cmprsk package in R (R Core
Team, Vienna, Austria) to compare the cumulative incidence of
disease-related deaths and treatment-related deaths between
groups, accounting for death resulting from other causes as a com-
peting event. Associations for each analysis were considered signifi-
cant at a 2-sided P value of ,.05.
Trial eligibility, treatment standards, and disease-related outcomes
generally differ in patients with stage I cHL and those with stage II
to IV disease.22 As such, outcomes for these individuals (n 5 22)
were analyzed separately; unless otherwise stated, reported analy-
ses include those with stage II to IV disease (n 5 222).
Results
Patient characteristics
Among the 244 eligible patients, median age at diagnosis was 68
years (range, 60-901), with 32% (n 5 78) between ages 70 and
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79 years and 10% (n 5 24) age $80 years; 57% were male. At
diagnosis, 63% had advanced-stage disease, 46% had B symp-
toms, and 96% had Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of 0 to 2. Sixty-nine percent had nodular
sclerosis, 19% had mixed cellularity, and 12% had other subtypes;
Epstein-Barr virus was detectable by immunohistochemistry and/or
peripheral blood in 39% of evaluable cases (n 5 98). These charac-
teristics were similar when restricted to patients with stage II to IV
disease.
Geriatric fitness
Before initiation of therapy, 31 patients (12%) had documented
loss of at least 1 basic or instrumental ADL, 40 (16%) had a
documented geriatric syndrome, and 16 (6.3%) had both ADL
impairment and a geriatric syndrome. In terms of medical comor-
bidities, median CIRS-G score was 5 (range, 0-22). One hun-
dred eleven (45%) had at least 1 comorbidity classified as







Characteristic n % n % n % P†
Male sex 113 46.3 85 44.7 28 51.9 .36
Age, y .004
Median 68 67 73
Range 60 to $90 60-88 60 to $90
Age category, y
60-69 140 57.4 123 64.7 18 33.3 Ref
70-79 79 32.4 55 28.9 24 44.4 .7
$80 24 9.8 12 6.3 12 22.2 .002
Stage
Limited (I-II) 89 36.5 70 36.8 19 35.2 Ref
Advanced (III-IV) 155 63.5 120 63.2 35 64.8 .77
B symptoms present 112 45.9 95 50.0 17 31.5 .01
ECOG PS
0-2 214 87.7 166 87.4 48 88.9 Ref
3-4 8 3.3 6 3.2 2 3.7 .03
Unknown/missing data 22 9.0 18 9.4 4 7.4 .65
Impaired ADLs/instrumental ADLs at baseline
No 206 84.4 163 85.9 43 79.6 Ref
Yes 30 12.3 19 10.0 11 20.4 .054
Unknown/missing data 8 3.3 8 4.2 0 0 —
Geriatric syndrome at baseline
No 195 79.9 156 82.1 39 72.2 Ref
Yes 43 17.6 28 14.7 15 27.8 .03
Unknown/missing data 6 2.5 6 3.2 0 0 —
CIRS-G total score
,10 196 80.3 153 80.5 43 79.6 Ref
$10 48 19.7 37 19.5 11 20.4 .02
Unknown/missing data 0 0 0 0 0 0 —
Conventional cHL regimens included AVD, ABVD, BV plus AVD (concurrent or sequential), and Stanford V.
†All P values are 2 sided.
ABVD (n=127)
AVD (n=29)






BV plus PD1 (n=16)
BV (n=5)
Figure 1. Frontline treatment regimens for stage II to IV disease. Common
alternative regimens enumerated in figure; regimens used for less than 5 patients
are not listed.
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severe (ie, individual CIRS-G category score of 3-4), and 44
(18%) had a total score of $10, indicating increased overall bur-
den. Geriatric fitness markers varied by age; patients age .70
years were more likely to have impaired ADLs (odds ratio [OR],
1.78; P 5 .09), CIRS total score of $10 (OR, 2.27; P 5 .001),
and/or a geriatric syndrome (OR, 2.82; P 5 .0002). Further anal-
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Figure 2. PFS and OS by geriatric fitness measures in stage II to IV disease. Time is listed in months for all figures. (A) PFS by ADL status. (B) OS by ADL status.
(C) PFS by documented geriatric syndrome. (D) OS by documented geriatric syndrome. (E) PFS by CIRS-G total score. (F) OS by CIRS-G total score.
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PS of 3 to 4 (n 5 7), and notably, only 1 patient underwent for-
mal GA before treatment.
Frontline therapy
Key clinical features are listed in Table 1, overall and by frontline
therapy. Common regimens (Figure 1) included ABVD (n 5 136;
56%), AVD (n 5 31; 13%), and CHOP (n 5 17; 7%). Six patients
(2.4%) received BV monotherapy; 19 (8%) received BV with AVD,
either concurrently (n 5 10) or sequentially (n 5 9). Of 9 patients
who did not receive systemic therapy, all received radiotherapy
alone for stage I (n 5 7) or II disease (n 5 2). Fifty-eight received
radiotherapy with systemic treatment; they predominantly had early-
stage cHL (n 5 41; 71%). In total, 12.6% (n 5 31) received BV as
part of frontline therapy, including 5 who also received upfront pro-
grammed death-1 inhibition. No patients received bleomycin, etopo-
side, doxorubicin, cyclophosphamide, vincristine, procarbazine, and
prednisone (BEACOPP; conventional or escalated) at any point dur-
ing therapy.
Outcomes and prognostication
With a median follow-up time of 3.1 years, median PFS and OS for
the total cohort have not yet been reached. Overall, 3-year PFS was
61.8%, and 3-year OS was 83.7%.
Geriatric fitness
Figure 2 highlights survival by different measures of geriatric fitness.
Patients with at least 1 documented impaired ADL had significantly
inferior PFS (hazard ratio [HR], 2.46; P 5 .0001) and OS (HR,
3.58; P , .0001) compared with those who were functionally profi-
cient. Other geriatric measures did not seem predictive of PFS but
showed modest OS impact. These included presence of a geriatric
syndrome (PFS: HR, 1.24; P 5 .44; OS: HR, 2.21; P 5 .03) and a
total CIRS-G score of $10 (PFS: HR, 1.05; P 5 .87; OS: HR,
2.11; P 5 .03). Patient characteristics listed in Table 2 were then
included in backward-elimination multivariable Cox proportional haz-
ards models for PFS and OS, respectively, where only ADL impair-
ment continued to correlate significantly with either end point (PFS:
multivariable HR, 2.13; P 5 .007; OS: multivariable HR, 2.52; P 5
.02). Alternative CIRS-G total score thresholds were not predictive
of PFS, nor were previously reported scoring systems in elderly
patients with lymphoma focusing on individual CIRS-G catego-
ries6,23 (data supplement).
Conventional vs alternative frontline therapy
Recipients of conventional cHL regimens showed superior PFS
(HR, 0.46; P 5 .0007) and OS (HR, 0.31; P 5 .0003) compared
with those treated with alternative regimens (Figure 3). Patient age
group (age 60-69 vs $70 years) did not affect survival outcomes
after conventional regimens (PFS: HR, 0.88; P 5 .63; OS: HR,
0.73; P 5 .55). Assessed across all frontline therapies, there was
no significant age-related PFS difference (HR, 0.81; P 5 .35),
although there was a trend toward longer OS in patients age ,70
years (HR, 0.53; P 5 .052). Given there were relatively few patients
age $80 years, further subdivision by age was not performed.
When adjusting for ADL status, conventional regimens continued to
show improved PFS (adjusted HR, 0.59; 95% confidence interval
[CI], 0.36-0.94; P 5 .03) and OS (adjusted HR, 0.34; 95% CI,
0.17-0.69; P 5 .003) vs alternative therapies.
To assess the relative efficacy of CHOP compared with other thera-
pies, a separate 3-arm comparison was performed for PFS and OS
(data supplement). CHOP demonstrated inferior PFS compared
with conventional regimens (HR, 0.28; P 5 .02), with no significant
difference in OS (HR, 0.86; P 5 .84). In contrast, non-CHOP alter-
native therapies were similar to CHOP in terms of PFS (HR, 1.46;
P 5 .46), and there was a nonsignificant trend toward improved
OS with CHOP vs non-CHOP alternative regimens (HR, 0.33; P 5
.13). Stratified analysis by ADL status was not performed because
of the low sample size.
Stage I disease
Twenty-two patients (9% of total cohort) had stage I disease at
diagnosis; median age was 71 years (range, 60-88), with 13
patients (59%) age .70 years. A majority (n 5 21; 95%) received
radiotherapy, and 14 (64%) received systemic therapy (range, 2-4
cycles); the latter was most commonly ABVD (n 5 9) and also
included AVD (n 5 2) and CHOP (n 5 1), all with radiotherapy.
Two patients received BV, 1 with radiotherapy and 1 with benda-
mustine. Overall response for those with stage I disease was 95%
(n 5 21), with 91% (n 5 20) achieving a complete response (CR).
Two-year PFS and OS were 82% and 95%, respectively; relapses
within the first 2 years of completing therapy (n 5 4; 18%) were
evenly divided between patients who received ABVD with radiother-
apy and those who received radiotherapy alone. Long-term out-
comes in this cohort remain unknown because of the excellent early
outcomes and limited follow-up thus far.
Table 2. Analysis of survival by baseline patient characteristics
PFS OS
Patient characteristic HR 95% CI P HR 95% CI P
Male sex 1.19 0.78-1.80 .42 1.44 0.76-2.71 .26
Age 60-69 vs $70 y 0.81 0.53-1.23 .31 0.59 0.29-1.06 .07
Advanced stage 1.75 1.14-2.70 .02 1.75 0.92-3.33 .12
Impaired ADLs/instrumental ADLs 2.11 1.03-4.30 .006 3.58 1.42-8.92 ,.0001
Geriatric syndrome 1.24 0.70-2.18 .44 2.21 0.88-5.54 .03
CIRS-G total ,10 vs $10 1.05 0.62-1.77 .87 2.11 0.92-4.85 .03
Multivariable Cox proportional hazards model (backward elimination)
Impaired ADLs/instrumental ADLs 2.13 1.23-3.69 .007 2.52 1.13-5.58 .02
All P values are 2 sided.
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Toxicity
Low-grade toxicities are common if not expected with cHL therapy;
such events are not reported here unless otherwise associated with
clinical outcomes. Severe toxicity leading to early treatment discon-
tinuation (treatment-limiting toxicity [TLT]) was noted in 15% (n 5
36) of patients. Eight patients (3.2%) experienced treatment-related
mortality (TRM), including 3 as a result of bleomycin-related lung
injury. TLTs occurred more commonly in those with CIRS-G of $10
(28% vs 12%; P 5 .016), those with a geriatric syndrome (28% vs
13%; P 5 .02), and those age $70 years (25% vs 8%; P 5 .001).
ADL impairment also trended toward higher incidence of TLT but
did not meet statistical significance (27% vs 13%; P 5 .096). Multi-
variable analysis of TLTs by age ($70 vs ,70 years), presence of a
geriatric syndrome, and high CIRS-G total score found that only
age remained significant (multivariable HR, 3.1; P 5 .004), with a
nonsignificant trend for CIRS-G of $10 (multivariable HR, 2.2; P 5
.059). Most TLTs were infectious in nature (n 5 19; 52.8%), with or
without associated neutropenia; other hematologic toxicities (eg,
severe anemia) were cited in only 1 other treatment discontinuation.
Cardiac toxicities were rare (n 5 11) but tended to be treatment
limiting (n 5 8; 73%).
TLT was associated with shorter treatment duration by a median of
2 cycles (6 vs 4 cycles; P , .0001). This in turn resulted in a lower
CR rates (50% vs 77%; P , .0001) as well as inferior PFS (HR,
3.19; 95% CI, 2.00-5.09; P , .0001) and OS (HR, 3.80; 95% CI,
1.94-7.45; P 5 .0001). When evaluating TLT along with ADL status
and achievement of a CR in a multivariable model, only response to
frontline therapy remained significant for PFS (adjusted HR, 0.17; P
, .0001) or OS (adjusted HR, 0.30; P 5 .003).
Bleomycin lung injury
ABVD recipients received a median of 7 bleomycin doses (range, 1-
14), and 26 (18.4%) had documented pulmonary toxicity. Although
uncommon, incidence of bleomycin lung injury was higher among
men (25.4% vs 11.4%; P 5 .03) and was not significantly associ-
ated with any other individual factor, including age, stage, smoking
history, pulmonary CIRS-G score, number of bleomycin doses, or
number of chemotherapy cycles (data not shown).
TRM
Eight patient deaths (3.3% of total cohort) were attributed to com-
plications of HL therapy. Median age of patients who experienced
TRM was 72.5 years (range, 61-83). TRM was most common after
receipt of ABVD (n 5 7); 3 deaths after ABVD were attributed to
bleomycin lung injury. One patient had a pretreatment ECOG PS of
3, 3 (37.5%) had CIRS-G of $10 (each with ECOG PS of 0-2),
and 2 (25%) had impaired instrumental ADLs and/or a known geri-
atric syndrome before frontline therapy. Three patients experienced
TRM after presenting initially with ECOG PS of 0 to 2, CIRS-G of
,10, and intact ADLs.
A competing-risk analysis was performed to compare deaths result-
ing from disease-related, treatment-related, and other causes, which
showed significant improvement in disease-related survival after
conventional cHL regimens (HR, 0.29; P 5 .02). Although there
was a suggestion that patients with high CIRS-G or a geriatric syn-
drome were at increased risk for death resulting from alternative
causes, this was not significant on multivariate analysis (data
supplement).
Discussion
To our knowledge, these data represent 1 of the largest detailed
analyses of older cHL patients in the modern era. Most patients in
this study derived significant benefit from conventional cHL regi-
mens, and many remained disease free at the time of last follow-up.
We believe a significant portion of these individuals may be cured
of their lymphoma, because their responses have been observed
beyond 5 years. Importantly, a number of these individuals with
durable responses are age .70 years, a group of patients who, if
treated according to their chronologic age, may not have been
offered potentially curative therapy. Given the substantial survival
benefit seen with conventional therapies, undertreatment based
solely on age thus presents a major risk to older cHL patients, and
such decisions should require justification based on physiologic
measures of fitness rather than age alone.
This in many ways echoes modern experiences in treating older
patients with diffuse large B-cell lymphoma (DLBCL), where
anthracycline-based therapy is a clear standard of care, even in
patients of advanced age.24,25 Because of low numbers, analysis
was limited for those age .80 years in this cohort, and further study
is warranted. Notably, there is no mini-CHOP equivalent when pre-
scribing an AVD-based regimen, and as mentioned, there are signifi-
cant differences in dose density between AVD and CHOP (eg,
chemotherapy every 3 vs every 2 weeks, respectively), which can
affect respective therapeutic outcomes in cHL.20,24 Common dose
modifications in older cHL patients include avoiding chemotherapy
escalation (no patient in this cohort received standard or escalated
BEACOPP) as well as limiting bleomycin exposure to a maximum of
4 doses.22 The latter was clearly not observed in this cohort, where
the median bleomycin course was 7 doses, and 86 (63%) of 136
ABVD recipients received $5 doses. Of note, bleomycin lung injury
as an entity is not well defined; we considered this diagnosis as any
reported pulmonary toxicity in a bleomycin recipient, although
numerous definitions have been employed, with rates varying from
9.3% to 91% across studies.8,26,27 We interpret the relatively low
rates of bleomycin lung injury in this context to be in part a conse-
quence of this lack of consensus on a definition as well as a
byproduct of retrospective collection, although administration of up
to 4 bleomycin doses, which the current National Comprehensive
Cancer Network guidelines22 list as appropriate for select older
patients, seemed to be well tolerated in this study.
Although older patients showed significant benefit overall with more
aggressive therapy, this is not to say that age and age-related fac-
tors do not affect treatment considerations. ADL impairment was
seen more commonly with advancing age, and the impact of other
geriatric measures on treatment efficacy by itself seems more
nuanced and challenging to quantify. Toxicities showed a consistent
Figure 3. PFS and OS by frontline treatment regimen in stage II to IV disease. Time is listed in months for all figures. (A) PFS by frontline treatment regimen. (B)
OS by frontline treatment regimen. (C) PFS in conventional (conv) regimen recipients age ,70 vs $70 years. (D) OS in conv regimen recipients age ,70 vs $70 years.
(E) PFS by ADL status and frontline regimen. (F) OS by ADL status and frontline regimen. Tx, treatment.
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relation to presence of a geriatric syndrome and high burden of
medical comorbidities, especially for toxicities that limited further
planned therapy. Risk of such TLT showed a clear increase with
advancing age, and the truncation of treatment length even by 1
cycle led to inferior responses and, by extension, to shorter PFS
and OS. Of note, few patients (15%) received novel agents with
frontline therapy, and it remains unclear whether 6 cycles will remain
the optimal treatment duration when such agents are included in
the upfront setting.
Only 1 patient in this large sampling of US academic cancer cen-
ters underwent formal GA before therapy. Despite rising calls for
GA incorporation into clinical trials and routine care for older
patients with cancer across the board,12,17 this lack of GA use may
reflect the paucity of data regarding how such measures would
inform therapy in lymphoma patients, including cHL. Several cHL
studies have incorporated at least some GA components, with the
emergence of medical comorbidities and ADL status as the most
straightforward predictors of treatment outcomes.9,10,14,15 The
recently reported Elderly Prognostic Index (EPI), developed for older
patients with DLBCL, highlights a potential framework to consider28;
biologic and functional differences likely exist between older popula-
tions with DLBCL and cHL, and further study is needed to assess
the utility of the EPI in the latter context. We compared the CIRS-G
criteria used in the EPI and found the total score to be more predic-
tive of severe toxicity, although histologies differ between studies,
and our finding is potentially biased as a result of retrospective col-
lection. Other factors such as gait speed, cognition, and nutrition
have all been evaluated in geriatric hematology, if not specifically in
the context of cHL,29-32 and all are notably omitted from the EPI.
Our data suggest that routine clinical practice at least in large aca-
demic centers in the United States rarely leverages these fitness
markers at present to guide therapy for older cHL patients. This is a
key area for future study, perhaps most importantly the study of how
GA may help guide decisions on therapeutic intensity and which
tests and scoring thresholds to use in order to optimize disease-
related outcomes and tolerability with cHL-directed therapy.
This study had several important limitations, in part because of its
retrospective design and the biases inherent in this approach. As
mentioned, only 1 patient underwent comprehensive GA; we other-
wise relied on retrospective collection of comorbidities, geriatric syn-
dromes, and ADL impairment, which was dependent on provider
documentation. As such, we suspect our study underestimates
these geriatric measures by identifying only the most significant
impairments and that more sensitive documentation and/or higher
use of GA may produce different outcomes. Our cohort included
low numbers of patients age .80 years, which is likely due to refer-
ral patterns of this patient population to academic medical centers
in the United States. Regarding use of novel agents, this study was
not powered to compare sequential vs concurrent administration of
BV with AVD chemotherapy, although cross-trial comparisons sug-
gest sequential administration may be better tolerated in older
patients. We were also unable to adequately capture incidence,
severity, and functional implications of treatment-related neuropathy;
this remains of critical interest, especially with BV-based therapy,
and warrants further study, especially with prolonged exposure.
Given the already extensive data collection for each patient per site,
we were unable to collect additional treatment details such as che-
motherapy dose levels or growth factor use. Patients were all seen
at academic medical centers; although a subset received at least
some of their treatment at affiliated community sites, this does select
for individuals willing and able to seek care at such locations.
Conventional chemotherapy (ABVD, AVD, or BV plus AVD) should
be considered standard of care for fit older patients with cHL, irre-
spective of chronologic age. Risk of inferior outcomes resulting from
TLT is higher in those with high medical comorbidities or a geriatric
syndrome. Further prospective study is needed to define fitness in
this context using GA and to evaluate the potential role of GA in
guiding therapeutic intensity as frontline treatments evolve.
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